News about Market

India, Brazil Ink MoU to Deepen Regulatory Cooperation in Pharma and Medical Products

India, Brazil Ink MoU to Deepen Regulatory Cooperation in Pharma and Medical Products

India’s CDSCO and Brazil’s ANVISA exchanged MoU in the presence of Prime Minister Narendra Modi and President Luiz Inácio Lula da Silva to strengthen regulatory cooperation in pharmaceuticals and medical products.

Market | 23/02/2026 | By News Bureau 126

Nektar Therapeutics Partners with University of California, San Francisco to Advance TNFR2 Research in Multiple Sclerosis

Nektar Therapeutics Partners with University of California, San Francisco to Advance TNFR2 Research in Multiple Sclerosis

Nektar Therapeutics and UCSF collaborate to study TNFR2 agonist NKTR-0165 in multiple sclerosis, aiming to explore its potential for neuroprotection and reduced neurodegeneration.

Market | 18/02/2026 | By News Bureau 160

Johnson & Johnson Secures FDA Approval for Monthly RYBREVANT FASPRO Dosing in EGFR-Mutated Lung Cancer

Johnson & Johnson Secures FDA Approval for Monthly RYBREVANT FASPRO Dosing in EGFR-Mutated Lung Cancer

Simplified once-monthly schedule for RYBREVANT FASPRO matches bi-weekly efficacy, reduces clinic visits and maintains a strong safety profile.

Market | 18/02/2026 | By News Bureau 116

Newron Pharmaceuticals Secures Euro 38 Million to Advance Phase III Schizophrenia Programme

Newron Pharmaceuticals Secures Euro 38 Million to Advance Phase III Schizophrenia Programme

Newron Pharmaceuticals strengthens its funding base with a multi-tranche equity raise to support late-stage development of evenamide in treatment-resistant schizophrenia.

Market | 17/02/2026 | By News Bureau 134

Hikal Ltd posts quarterly loss as pharma manufacturing operations return to recovery

Hikal Ltd posts quarterly loss as pharma manufacturing operations return to recovery

Hikal Ltd reported a net loss of INR 5.9 crore in the third quarter of FY26, compared with a profit of INR 17.2 crore in the corresponding quarter last year. Despite the loss, total revenue from operations increased 10.4 per cent year on year to INR 494.3 crore, up from INR 447.7 crore.

Market | 16/02/2026 | By Darshana 155

STADA and Bio-Thera Secure EU Marketing Approval for Golimumab Biosimilar Gotenfia

STADA and Bio-Thera Secure EU Marketing Approval for Golimumab Biosimilar Gotenfia

European Commission authorises Gotenfia, referencing Simponi, for multiple autoimmune diseases across EU and EEA markets.

Market | 16/02/2026 | By News Bureau 167

Lupin Posts 37 percent Q3 Profit Growth on Record US Sales

Lupin Posts 37 percent Q3 Profit Growth on Record US Sales

Lupin Limited reported a 37.4 percent year-on-year increase in net profit for the third quarter ended December 31, 2025, reaching INR 1,180.5 crore, compared with INR 858.9 crore in the same quarter last year.

Market | 13/02/2026 | By Darshana 199

Pharma-to-Wellness Play: USV Secures Controlling Interest in Wellbeing Nutrition

Pharma-to-Wellness Play: USV Secures Controlling Interest in Wellbeing Nutrition

USV has acquired a 79 percent stake in Wellbeing Nutrition, a leading consumer healthcare and nutrition company, in a deal valued at INR 1,583 crore. The acquisition marks a strategic move by USV to strengthen its presence in the fast-growing consumer wellness and nutrition segment.

Market | 12/02/2026 | By Darshana 229

Iqvia and Duke Clinical Research Institute Partner to Advance Obesity and Cardiometabolic Clinical Trials

Iqvia and Duke Clinical Research Institute Partner to Advance Obesity and Cardiometabolic Clinical Trials

Iqvia and DCRI have formed a strategic collaboration to enhance the design and execution of obesity and cardiometabolic clinical trials, combining global operational capabilities with academic research expertise.

Market | 12/02/2026 | By News Bureau 191

IOL Chemicals and Pharmaceuticals Reports Q3 and 9M FY26 Results

IOL Chemicals and Pharmaceuticals Reports Q3 and 9M FY26 Results

IOL Chemicals and Pharmaceuticals reported strong Q3 and nine-month FY26 results, with profit before exceptional items rising 39 percent year-on-year, supported by margin expansion and improved operational performance.

Market | 12/02/2026 | By News Bureau 149

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members